Science & Technology
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeutics
Department of Health and Human Services — National Institutes of Health
Opportunity #: 2R44AG071040-02
Award Ceiling
$2.5M
Award Floor
$2.5M
Close Date
Feb 28, 2026
Total Funding
$2.5M
Expected Awards
1
Posted Date
Mar 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-2R44AG071040-02
Description
SBIR Phase Phase II award: "Direct protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeutics" awarded to ATUX ISKAY GROUP LLC in PLAINSBORO, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,516,671. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.